Numerous victims of Xarelto (rivaroxaban), a new generation anticoagulant, have come forward with allegations against Janssen Pharmaceuticals for falsely marketing the drug as safe. This isn’t the first time an anti-coagulant has been touted as the latest and greatest, only to discover that manufacturers failed to warn doctors and patients about the potential for life-threatening bleeds. In 2014, the makers of Pradaxa were forced to pay more than $650 million as a result of numerous lawsuits, and now Janssen Pharmaceuticals is facing similar action for the same misinformation. Rather than withdrawing Xarelto from the marketplace, Janssen Pharmaceuticals and Johnson & Johnson continued to promote and aggressively market the drug as safe even after instances of patient injuries began to mount.
All anticoagulants, (commonly known as blood thinners) are used to prevent blood clots and can result in bleeding that is difficult to stop. The problem, however, is that unlike other drugs, Xarelto does not have a reversal antidote to manage bleeding. The blood thinner Warfarin (Coumadin), for example, has been used for several years. In the case of a fatal bleeding event, Warfarin’s effects can be reversed and managed when a patient is given the antidote vitamin K.
Doctors, medical staff, and patients were not made aware of the risks of taking Xarelto or of any reversal methods to stabilize a patient in the event of a serious complication. In just 30 days, more than 1,800 ads for Xarelto were shown, paid for by Janssen Pharmaceuticals. Many of these ads claimed that Xarelto was a safer, more convenient alternative to the decades-old drug Warfarin.
Janssen Pharmaceuticals marketed Xarelto as a “once daily” dosage to all patients, regardless of medical history, age, or other factors that could affect the way that a medication is tolerated. This claim has resulted in injury and death for thousands of patients who were unaware of the risks associated with taking Xarelto. The FDA first approved Xarelto in 2011 for patients at risk of deep vein thrombosis (DVT) undergoing knee and hip replacements, stroke in patients with atrial fibrillation (AF), and those at risk of pulmonary embolism (PE).
In 2013, the FDA issued a warning to Johnson & Johnson (on behalf of Janssen Pharmaceuticals) for an ad that ran in in the January/February 2013 issue of WebMD magazine. The FDA stated that the ad was false and misleading because it minimized the risks that are associated with Xarelto. The ad also falsely claimed that the drug required no dosage adjustments. However, in the prescribing Information section of the Medication Guide, it is recommended that the dose should be lowered to 15 mg once a day for patients with renal impairment.
Unfortunately, due to Janssen Pharmaceuticals’ failure to warn medical staff and patients, thousands of people have been injured by the drug’s effects and inability to stabilize patients who have taken it. Xarelto use has been linked to…
If you or a loved one have suffered from any of these side effects while taking Xarelto, you may be eligible to file a claim against Janssen Pharmaceuticals and entitled to compensation for injuries.
Bronx attorneys Macaluso & Fafinski are experienced in representing clients who have been victims of marketing defect and product liability. If you or your loved one took Xarelto and suffered from a serious bleeding event in the Bronx, and you were not warned of these severe side effects prior to use, we will review your case at no cost to determine if you or your loved one may be eligible for compensation for injuries, medical bills, lost income, pain, and suffering. Many who have suffered severe side effects from Xarelto are coming forward to seek justice and appropriate compensation.
To arrange a free evaluation of your case and explore your legal options, call Macaluso & Fafinski today at 718.364.4000 (in the Bronx) or 212.480.9000 (from elsewhere in New York), or simply fill out our convenient online form, and we will respond as soon as possible. The offices of Macaluso & Fafinski are conveniently located to serve the five-borough area and its residents.